FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018938087> ?p ?o ?g. }

• W2018938087 endingPage "93" @default.
• W2018938087 startingPage "87" @default.
• W2018938087 abstract "Human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic inflammatory myelopathy. The pathophysiology of HAM/TSP is not yet fully understood; therefore, effective therapy remains a challenging issue. This study was designed to evaluate the efficacy of interferon-alpha (IFN-α) in HAM/TSP patients in the Northeast of Iran. Forty-nine patients with a definite diagnosis of HAM/TSP were enrolled in this clinical trial. For six months, the patients received three million international units of subcutaneous IFN-α-2b per each injection. The dose regimen was daily injection for the first month, three times administration per week for the months 2 and 3, twice weekly injection for the months 4 and 5 and weekly injection for the sixth month. The clinical and laboratory responses were evaluated based on neurologic examinations and immunovirological markers. IFN-α had significant but temporary effect on the motor and urinary functions of the patients. Comparing to the baseline values, proviral load was significantly decreased one month after treatment in responders (495.20±306.87 to 262.69±219.24 p=0.02) and non-responders (624.86±261.90 to 428.28±259.88 p=0.03). Anti-HTLV-1 antibody titers were significantly decreased among responders (1152.1±200.5 to 511.6±98.2 p=0.009) and non-responders (1280.1±368.1 to 537.6±187 p=0.007). Flow cytometry showed no significant changes in CD4, CD8, CD4CD25 and CD16CD56 counts with IFN-α. The positive impact of IFN-α was observed during the treatment period with significant effects on some clinical aspects of HAM/TSP." @default.
• W2018938087 created "2016-06-24" @default.
• W2018938087 creator A5000216278 @default.
• W2018938087 creator A5002139529 @default.
• W2018938087 creator A5006789676 @default.
• W2018938087 creator A5010305315 @default.
• W2018938087 creator A5010705520 @default.
• W2018938087 creator A5012289865 @default.
• W2018938087 creator A5022276754 @default.
• W2018938087 creator A5023355769 @default.
• W2018938087 creator A5030997252 @default.
• W2018938087 creator A5031193069 @default.
• W2018938087 creator A5039260981 @default.
• W2018938087 creator A5045802662 @default.
• W2018938087 creator A5058714645 @default.
• W2018938087 creator A5063491635 @default.
• W2018938087 creator A5076870164 @default.
• W2018938087 creator A5087343974 @default.
• W2018938087 date "2012-09-01" @default.
• W2018938087 modified "2023-09-27" @default.
• W2018938087 title "The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran" @default.
• W2018938087 cites W1508126495 @default.
• W2018938087 cites W1965244207 @default.
• W2018938087 cites W1980744027 @default.
• W2018938087 cites W1984615218 @default.
• W2018938087 cites W1991049176 @default.
• W2018938087 cites W1991941671 @default.
• W2018938087 cites W1998193590 @default.
• W2018938087 cites W2004149547 @default.
• W2018938087 cites W2014406183 @default.
• W2018938087 cites W2016837741 @default.
• W2018938087 cites W2019526141 @default.
• W2018938087 cites W2030973107 @default.
• W2018938087 cites W2033791581 @default.
• W2018938087 cites W2034134257 @default.
• W2018938087 cites W2058232749 @default.
• W2018938087 cites W2065141696 @default.
• W2018938087 cites W2066745725 @default.
• W2018938087 cites W2069667541 @default.
• W2018938087 cites W2077606955 @default.
• W2018938087 cites W2093350079 @default.
• W2018938087 cites W2121082919 @default.
• W2018938087 cites W2129566521 @default.
• W2018938087 cites W2130873978 @default.
• W2018938087 cites W2138952238 @default.
• W2018938087 cites W2154664865 @default.
• W2018938087 cites W2158187041 @default.
• W2018938087 cites W2166237978 @default.
• W2018938087 cites W2170051026 @default.
• W2018938087 cites W2261614924 @default.
• W2018938087 doi "https://doi.org/10.1016/j.jneuroim.2012.05.004" @default.
• W2018938087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22727800" @default.
• W2018938087 hasPublicationYear "2012" @default.
• W2018938087 type Work @default.
• W2018938087 sameAs 2018938087 @default.
• W2018938087 citedByCount "45" @default.
• W2018938087 countsByYear W20189380872013 @default.
• W2018938087 countsByYear W20189380872014 @default.
• W2018938087 countsByYear W20189380872015 @default.
• W2018938087 countsByYear W20189380872016 @default.
• W2018938087 countsByYear W20189380872017 @default.
• W2018938087 countsByYear W20189380872018 @default.
• W2018938087 countsByYear W20189380872019 @default.
• W2018938087 countsByYear W20189380872020 @default.
• W2018938087 countsByYear W20189380872021 @default.
• W2018938087 countsByYear W20189380872022 @default.
• W2018938087 countsByYear W20189380872023 @default.
• W2018938087 crossrefType "journal-article" @default.
• W2018938087 hasAuthorship W2018938087A5000216278 @default.
• W2018938087 hasAuthorship W2018938087A5002139529 @default.
• W2018938087 hasAuthorship W2018938087A5006789676 @default.
• W2018938087 hasAuthorship W2018938087A5010305315 @default.
• W2018938087 hasAuthorship W2018938087A5010705520 @default.
• W2018938087 hasAuthorship W2018938087A5012289865 @default.
• W2018938087 hasAuthorship W2018938087A5022276754 @default.
• W2018938087 hasAuthorship W2018938087A5023355769 @default.
• W2018938087 hasAuthorship W2018938087A5030997252 @default.
• W2018938087 hasAuthorship W2018938087A5031193069 @default.
• W2018938087 hasAuthorship W2018938087A5039260981 @default.
• W2018938087 hasAuthorship W2018938087A5045802662 @default.
• W2018938087 hasAuthorship W2018938087A5058714645 @default.
• W2018938087 hasAuthorship W2018938087A5063491635 @default.
• W2018938087 hasAuthorship W2018938087A5076870164 @default.
• W2018938087 hasAuthorship W2018938087A5087343974 @default.
• W2018938087 hasConcept C118552586 @default.
• W2018938087 hasConcept C126322002 @default.
• W2018938087 hasConcept C141071460 @default.
• W2018938087 hasConcept C159654299 @default.
• W2018938087 hasConcept C203014093 @default.
• W2018938087 hasConcept C2776178377 @default.
• W2018938087 hasConcept C2776392238 @default.
• W2018938087 hasConcept C2777604421 @default.
• W2018938087 hasConcept C2780775167 @default.
• W2018938087 hasConcept C2781413609 @default.
• W2018938087 hasConcept C2909179924 @default.
• W2018938087 hasConcept C32611913 @default.
• W2018938087 hasConcept C71924100 @default.
• W2018938087 hasConcept C90924648 @default.

• next